Gambino A
Department of Cardiovascular Surgery, University of Padua Medical School, Via Giustiniani 2, 35128 Padua, Italy.
Transplant Proc. 2003 Dec;35(8):3069-71. doi: 10.1016/j.transproceed.2003.10.041.
Little more than 30 years after the first human operation, heart transplantation continues to be the gold standard treatment for heart failure disease. During these years, surgical procedures and immunosuppressive treatment have improved and the survival rate continues to improve despite transplanting older and sicker patients. However, there are still many challenges that we are currently facing. Regarding organ shortage, donor heart acceptance criteria have been reconsidered. Better donor management could increase the organ pool, maximizing the use of hearts recovered from cadaveric donors. Concerning organ allocation, recent improvements in medical treatment could restrict transplantation procedures to the patients at greatest risk of dying. Controlling allograft rejection, vasculopathy, and malignancies are current challenges. Cyclosporine, azathioprine, and corticosteroids have been the mainstay of immunosuppression, but carry severe adverse systemic effects. Today, new pharmacologic agents have become available and hold the possibility to improve the length and quality of recipient life.
在首例人体心脏移植手术过去仅仅30多年后,心脏移植仍然是心力衰竭疾病的金标准治疗方法。在这些年里,外科手术和免疫抑制治疗都有了改进,尽管移植的患者年龄更大、病情更重,但存活率仍在不断提高。然而,我们目前仍面临许多挑战。在器官短缺方面,供体心脏的接受标准已被重新审视。更好的供体管理可以增加器官库,最大限度地利用从尸体供体获取的心脏。在器官分配方面,近期医疗水平的提高可以将移植手术限制在死亡风险最高的患者身上。控制同种异体移植排斥反应、血管病变和恶性肿瘤是当前面临的挑战。环孢素、硫唑嘌呤和皮质类固醇一直是免疫抑制的主要药物,但会带来严重的全身性不良反应。如今,新的药物已经问世,有望提高受体的生存时长和生活质量。